搜尋結果
VAXIGRIP TETRA is indicated for the prevention of influenza disease caused by the two influenza. virus subtypes and the two influenza B virus types contained in the vaccine for: active immunisation of adults, including pregnant women, and children from 6 months of age. and older,
2023 Profile of Sanofi's Vaccines Business Unit References World Health Organization (2019) Immunization Facts in Pictures. Accessed October 2022 MAT-GLB-2200131 v2 – 12/2022 Page updated December 2022 Continue to Your Health Follow us Back to ...
2018年3月8日 · Vaxigrip Tetra ® (Sanofi Pasteur) is a novel four-strain influenza vaccine belonging to the Vaxigrip ® family of influenza vaccines []. It is a quadrivalent split-virion inactivated influenza vaccine containing the purified HA and NA antigens from the four influenza virus strains recommended by the WHO [ 79 ].
- Emanuele Montomoli, Alessandro Torelli, Ilaria Manini, Elena Gianchecchi
- 10.3390/vaccines6010014
- 2018
- Vaccines (Basel). 2018 Mar; 6(1): 14.
2 天前 · Vaxigrip Tetra is a vaccine. This vaccine helps to protect you or your child against influenza (flu). Vaxigrip Tetra is used to prevent flu in persons of 6 months of age and older. If you are...
VAXIGRIP. Sanofi Pasteur Section 1.3.1 Clean Product Monograph 314 and 329 – VAXIGRIP®. Page 1 of 23 . PRODUCT MONOGRAPH . VAXIGRIP®. Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) . Suspension for Injection . Active Immunizing Agent for the Prevention of Influenza . ATC Code: J07BB02 . Manufactured by: . Sanofi Pasteur SA.
- 145KB
- 23
Abstract. VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).
This quadrivalent formulation of Vaxigrip contains two A and two B influenza strains (VaxigripTetra), and has a similar immunogenicity and safety profile to the trivalent formulation while offering broader protection due to the addition of the second influenza B strain.
